AI assistant
AVACTA GROUP PLC Regulatory Filings 2021
7507_rns_2021-03-03_dc1a63dd-0c84-4ab9-a309-592fa8a0e199.html
Regulatory Filings
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 0899R
Avacta Group PLC
03 March 2021
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Electronic Communications with Shareholders
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, announces that it has today posted a letter concerning electronic communications to its new shareholders that have become holders of ordinary shares in the Company since the last deemed consent letter was sent.
As part of Avacta's commitment to reducing the impact of its activities on the environment, whenever possible, the Company wishes to notify shareholders of its results and other news electronically.
The letter will be available on the Investors section of Company's website at www.avacta.com and sets out the actions to be taken by shareholders.
- Ends-
For further information from Avacta Group plc, please contact:
| Avacta Group plc | Tel: +44 (0) 844 414 0452 |
| Alastair Smith, Chief Executive Officer | www.avacta.com |
| Tony Gardiner, Chief Financial Officer | |
| finnCap Ltd (Nominated Adviser and Joint Broker) | Tel: +44 (0) 207 220 0500 |
| Geoff Nash / Giles Rolls - Corporate Finance Tim Redfern - ECM |
www.finncap.com |
| Stifel Nicolaus Europe Limited (Joint Broker) | Tel: +44 (0) 207 710 7600 |
| Nicholas Moore / Nick Adams / Fred Walsh / Ben Maddison | www.stifel.com |
| FTI Consulting (Financial Media and IR) | Tel: +44 (0) 203 727 1000 |
| Simon Conway / Stephanie Cuthbert | [email protected] |
| Zyme Communications (Trade and Regional Media) | Tel: +44 (0) 7787 502 947 |
| Katie Odgaard | [email protected] |
About Avacta Group plc - https://www.avacta.com
Avacta Group is developing novel cancer immunotherapies and powerful diagnostics based on its two proprietary platforms - Affimer® biologics and pre|CISION™ tumour targeted chemotherapies.
The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets, such as diagnostics and therapeutics, worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken to generate new antibodies and the reliance on an animal's immune response; poor specificity in many cases; their large size, complexity and high cost of manufacture.
Avacta's pre|CISION targeted chemotherapy platform releases active chemotherapy in the tumour, which limits the systemic exposure that causes damage to healthy tissues, and thereby improves the overall safety and therapeutic potential of these powerful anti-cancer treatments.
The Group comprises two divisions: The therapeutics development activities are based in Cambridge, UK and the Group is generating near-term revenues from Affimer reagents for diagnostics, bioprocessing and research, through a separate diagnostics business unit based in Wetherby, UK.
Avacta's Diagnostics Division works with partners world-wide to develop bespoke Affimer reagents for third party products. The Group is also developing an in-house pipeline of Affimer-based diagnostic assays including the AffiDX™ SARS-CoV-2 Lateral Flow Rapid Antigen Test and a BAMS™ SARS-CoV-2 Assay in partnership with Adeptrix Inc.
Avacta's Therapeutics Division is addressing a critical gap in current cancer treatment - the lack of a durable response to current immunotherapies experienced by most patients. By combining its two proprietary platforms the Group is building a wholly owned pipeline of novel cancer therapies deigned to be effective for all cancer patients. In 2021 Avacta will commence a phase 1 first-in-human, open label, dose-escalation and expansion study of AVA6000 Pro-doxorubicin, the Group's lead pre|CISION™ prodrug, in patients with locally advanced or metastatic selected solid tumours.
Avacta has established drug development partnerships with pharma and biotech, including a research collaboration with Moderna Therapeutics Inc., a multi-target deal with LG Chem worth up to $400m, a joint venture in South Korea with Daewoong Pharmaceutical focused on cell and gene therapies incorporating Affimer immune-modulators, a partnership with ADC Therapeutics to develop Affimer-drug conjugates and a collaboration with Point Biopharma to develop radiopharmaceuticals based on the pre|CISION™ platform. Avacta continues to actively seek to license its proprietary platforms in a range of therapeutic areas.
To register for news alerts by email go to www.avacta.com/investor-news-email-alerts
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRAEAXDDEFAFEFA